Patents by Inventor Timothy Heffernan
Timothy Heffernan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240360121Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: ApplicationFiled: March 6, 2024Publication date: October 31, 2024Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
-
Publication number: 20240165070Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: ApplicationFiled: September 6, 2023Publication date: May 23, 2024Inventors: Timothy HEFFERNAN, Jeffrey KOVACS, Nakia SPENCER, Christopher BRISTOW
-
Patent number: 11958849Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: GrantFiled: April 25, 2022Date of Patent: April 16, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
-
Patent number: 11786500Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: GrantFiled: May 21, 2021Date of Patent: October 17, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Timothy Heffernan, Jeffrey Kovacs, Nakia Spencer, Christopher Bristow
-
Patent number: 11713313Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: GrantFiled: July 1, 2020Date of Patent: August 1, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
-
Publication number: 20230124815Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: ApplicationFiled: April 25, 2022Publication date: April 20, 2023Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
-
Patent number: 11370786Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: GrantFiled: July 10, 2020Date of Patent: June 28, 2022Assignee: Board of Regents, The University of Texas SystemInventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
-
Publication number: 20220135967Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.Type: ApplicationFiled: January 20, 2022Publication date: May 5, 2022Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Dennis Buckley, Georg Winter, Andrew J. Phillips, Timothy Heffernan, James Bradner, Justin Roberts, Behnam Nabet
-
Patent number: 11293023Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.Type: GrantFiled: February 6, 2018Date of Patent: April 5, 2022Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Dennis Buckley, Georg Winter, Andrew J. Phillips, Timothy Heffernan, James Bradner, Justin Roberts, Behnam Nabet
-
Publication number: 20220016069Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: ApplicationFiled: May 21, 2021Publication date: January 20, 2022Inventors: Timothy HEFFERNAN, Jeffrey KOVACS, Nakia SPENCER, Christopher BRISTOW
-
Publication number: 20210301286Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.Type: ApplicationFiled: May 27, 2021Publication date: September 30, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
-
Patent number: 11046954Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.Type: GrantFiled: February 6, 2018Date of Patent: June 29, 2021Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
-
Patent number: 11045443Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: GrantFiled: June 3, 2020Date of Patent: June 29, 2021Assignee: Board of Regents, The University of Texas SystemInventors: Timothy Heffernan, Jeffrey Kovacs, Nakia Spencer, Christopher Bristow
-
Publication number: 20210122744Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: ApplicationFiled: July 1, 2020Publication date: April 29, 2021Inventors: Richard Thomas LEWIS, Philip JONES, Alessia PETROCCHI, Naphtali REYNA, Matthew HAMILTON, Michael J. SOTH, Timothy HEFFERNAN, Michelle HAN, Jason P. BURKE
-
Publication number: 20200407353Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: ApplicationFiled: July 10, 2020Publication date: December 31, 2020Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
-
Publication number: 20200368196Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: ApplicationFiled: June 3, 2020Publication date: November 26, 2020Inventors: Timothy HEFFERNAN, Jeffrey KOVACS, Nakia SPENCER, Christopher BRISTOW
-
Patent number: 10766892Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: GrantFiled: May 14, 2019Date of Patent: September 8, 2020Assignee: Board of Regents, The University of Texas SystemInventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
-
Patent number: 10738043Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: GrantFiled: October 5, 2018Date of Patent: August 11, 2020Assignee: Board of Regents, The University of Texas SystemInventors: Richard Thomas Lewis, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Matthew Hamilton, Michael J. Soth, Timothy Heffernan, Michelle Han, Jason P. Burke
-
Patent number: 10722487Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: GrantFiled: October 18, 2018Date of Patent: July 28, 2020Assignee: Board of Regents, The University of Texas SystemInventors: Timothy Heffernan, Jeffrey Kovacs, Nakia Spencer, Christopher Bristow
-
Publication number: 20190274993Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.Type: ApplicationFiled: October 18, 2018Publication date: September 12, 2019Inventors: Timothy HEFFERNAN, Jeffrey KOVACS, Nakia SPENCER, Christopher BRISTOW